Moreover, changes in cytokine levels, such as IL-6 (interleukin 6), IL-10 (interleukin 10), and IL-13 (interleukin 13), are associated with treatment-related toxicities, notably fatigue and endothelial dysfunction [63]. This evidence concerns the gene IL6 and endothelial dysfunction.